| |
Septemeber 8-11, 2025 | Philadelphia, PA Where biotech breakthroughs meet pharma scale. Dive into dynamic discussions on translational science, dealmaking, and the innovation shaping the next generation of therapies. Register now to connect and collaborate. .png)
|
|
Today’s Big NewsJun 4, 2025 |
|
Monday, June 16, 2025 | 12pm ET / 9am PT Join a candid and informative discussion between precision medicine experts. They will share lessons learned and concrete opportunities to transform clinical trial design, execution and outcomes. Register now. 
|
|
| By Angus Liu As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes how far the fanfare will spread. |
|
|
|
By Kevin Dunleavy Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, scoring an FDA approval to expand its use to all patients with metastatic castration-sensitive prostate cancer, with or without added chemotherapy. |
By Heather Landi The company has hit significant milestones in the past year. Neuralink says its conducted more human clinical trials, implanting its brain chips in five patients with severe paralysis. |
By Zoey Becker With the deal, Lilly can use Camurus' long-acting delivery technology on up to four of its own incretin compounds to develop injections in the cardiometabolic health space. |
|
Wednesday, June 11, 2025 | 11am ET / 8am PT Join us for a deep dive into the strategies and best practices for maximizing valuation by improving productivity in modern clinical trials. We'll discuss key ways to achieve tangible productivity gains, accelerate timelines, and avoid costly protocol amendments or clinical failures. Register now to learn expert tips for maximizing efficiency and effectiveness. 
|
|
By Andrea Park Pharmas looking to recruit younger workers should meet Gen Z where they’re at: namely, TikTok and Instagram, according to a new report from the Association of the British Pharmaceutical Industry. |
By James Waldron Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences drug can hold its own against FDA-approved products Seysara and doxycycline. |
By Zoey Becker Lakshmi Panagiotakopoulos, M.D., hit the exit from her co-leading role in the CDC’s Advisory Committee on Immunization Practices work group on COVID vaccines, according to Reuters. |
By James Waldron Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only covalent Werner helicase inhibitor to have made it into the clinic. |
By Nick Paul Taylor Failures at Novartis have prompted the U.K. marketing watchdog to warn that “companies should be on high alert” when working with third parties to promote materials about medical conferences. |
By Andrea Park Almost exactly a year after launching its Obesity Association, the American Diabetes Association has recruited Novo Nordisk for support. |
By Joseph Keenan Antheia, a biomanufacturer that makes a key ingredient for the opioid overdose treatment Narcan, reeled in $56 million in series C financing it said will be used to expand manufacturing operations in the U.S. and to start new programs in Singapore. |
By Darren Incorvaia Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss space. The Bay Area biotech has entered an option agreement with Chinese firm JiKang Therapeutics to potentially license a new apelin receptor (APJ) agonist nanobody. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we break down first-quarter Big Pharma earnings, recap the latest gene therapy developments and preview what’s ahead at ASCO. |
|
|---|
|
|
|
Tuesday, June 17, 2025 | 11am ET / 8am PT Join experts from NIBRT and Securecell AG to explore how advanced Process Analytical Technologies (PAT) are transforming bioprocessing. Register now. 
|
|
Whitepaper We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
